Imugene, a clinical-stage immuno-oncology company, announced that the first patient had been dosed in its Phase 1 trial for treating bile tract cancer.

The trial is being conducted at St. Vincent's Hospital, Melbourne, and will enrol 10 patients.

The trial is an extension of the metastatic advanced solid tumours Phase 1 study, following early positive responses in gastrointestinal cancers, especially cholangiocarcinoma, using Imugene's cancer-killing virus CF33.

"We look forward to now advancing to the higher doses in the trial to gather further key data and make a genuine difference to patients in need of innovative treatment options," stated Imugene Managing Director and CEO Leslie Chong.